Linked Life Data

12120095

Source:http://linkedlifedata.com/resource/pubmed/id/12120095

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2002-7-17
pubmed:abstractText
The glycosaminoglycan heparin has been used in the clinic as an anticoagulant for more than 50 years. A fully characterized sequence in native heparin is known to be responsible for this activity. However, heparin is a complex polysaccharide, which has an array of properties that are unrelated to its anticoagulant activity. Recent research has provided us with an increased understanding of the specific structural requirements for the various actions of heparin, indicating that it might be possible to create 'tailor-made' sequences based on the heparin template to isolate specific therapeutic activities. This research should provide the basis for novel drug treatments for a range of diseases, including cancer and various inflammatory diseases.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1474-1776
pubmed:author
pubmed:issnType
Print
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
140-8
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Novel drug development opportunities for heparin.
pubmed:affiliation
Sackler Institute of Pulmonary Pharmacology, GKT School of Biomedical Sciences, King's College London, London SE1 9RT, UK. rebecca.lever@kcl.ac.uk
pubmed:publicationType
Journal Article